NAIMIT (acronym for Natural Immune Modulation for Intervention in Type 1 Diabetes) is a large-scale collaborative programme of the 7th framework from the European Commission. The aim of the consortium is to bring together a group of leading European researchers spanning the field from genetics, through pancreatic beta-cell, dendritic cells and T-cell biology, towards clinical interventions. The ultimate goal is to develop novel and personalised interventional therapies in recent-onset type 1 diabetic patients, with minimal immune system interference, leading to beta-cell protection and restoration, based on a solid understanding of the disease pathogenesis, enabling experimental findings to be adopted for clinical applications.
interventions to achieve beta-cell protection and restoration should realise these goals through modulation of the immune system of the patient to a minimal degree in order to avoid severe disturbances of immune surveillance mechanisms leading to intolerable side effects.
The present state of our understanding of the pathogenesis of T1D indicates that, in principle, therapeutic success is achievable and that interference in the progressive loss of beta-cell mass in newly diagnosed T1D patients is within reach. This requires innovative approaches that operate with a minimal degree of interference in the general functions of the immune system. In order to move the field forward in this respect, we have proposed a series of studies that represent a novel and integrated approach.
The underlying concept for the therapeutic interventions to be developed in this proposal was the central role of the immune system in T1D, but we also recognised the important role that the beta-cell adopts, as a partner actively contributing to its own demise (see Figure 1 ). This should undoubtedly be taken into account when designing strategies for therapeutic interventions for beta-cell protection and restoration.
The concept of a key role for both the immune system and the beta-cell highlights the need for a 'multiple hit' approach to disease prevention.
This approach should include both modulation and re-education of the immune system, boosting of beta-cell defenses against autoimmune damage and arresting the pro-inflammatory dialogue between immune cells and beta-cells.
The NAIMIT Objectives
The NAIMIT project followed from the concept proposed: if the interplay between the beta-cell and the immune system are central to the pathogenesis of the disease, both partners must be studied. Moreover, different parts of the immune system may be studied at the same time and if we want to interfere in a disease like T1D, where a treatment (although not perfect and cumbersome) exists, namely insulin therapy, we will only accept interventions that are soft and virtually without side effects. Finally, the use of steroids like VitD as immune modulators opens the road to personalised medicine, on the basis of genetic markers. Of interest, we decided to put 'the building of a consortium' by itself as one of the objectives, and in hindsight this is probably one of the most important objectives: to bring together a group of experts around one theme, thus creating synergy in methods and in ideas. Thus, the specific objectives were defined as: 
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Viral infections or other triggers can initiate a hyperactive response towards the beta-cells, releasing beta-cell antigens and possibly also chemokines that may contribute to the homing and activation of T lymphocytes and antigen-presenting cells (APCs) into the islets. The beta-cell antigens are presented in association with class II major histocompatibility complex (MHC) molecules to CD4+ T lymphocytes after being processed by the dendritic cells (DCs). DCs release interleukin (IL)-12, activating CD4+ T effector (Te) cells, which in turn release interferon (IFN)-g and IL-2. Migratory macrophages and CD8+ T lymphocytes become cytotoxic (Tc
The Relation of NAIMIT with the European Commission
From the beginning, the EC assigned one scientific officer to NAIMIT.
This person knew the project and the consortium well and was our liaison with the EC. An intense relationship grew with the coordinator, with direct email and phone contact to discuss any concerns of administration and finances. This relationship was crucial to the success of NAIMIT as questions were answered immediately and administrative burden was alleviated. Because, indeed, administrative burden exists, also in the coordination office, not only an administrative coordinator was appointed, but also a financial officer, with a financial office behind her. In addition, all partners had their financial officers also standing by and guiding the principal investigators in matters of financial reporting and auditing. The EC has very strict rules, which are sometimes surreal for researchers, so financial and administrative experts are essential as part of the team.
The Glue within NAIMIT
As stated, the NAIMIT consortium was a true consortium, but still, the 
Work Package 2 -Restoring the T-cell Balance
This WP aims to restore the T-cell balance through an antigenspecific route that avoids global immune suppression. It builds upon the emerging programme of peptide immunotherapy (PIT), in which naturally processed and presented peptide fragments from major beta-cell auto-antigens are administered intradermally to promote the generation of islet-specific Tregs (IS-Tregs). Use of multiple peptides to enhance the power and breadth of the approach will be a major asset. 
Work Package 3 -T-cell Receptor-directed Immunotherapy
In this WP, the body's own system of recognising antigens on the surface of cells, namely the T-cell receptor (TCR), is being exploited by a very innovative technology, developed by the SME partner ImmunoCore. is a significant achievement for a sub-optimal autoimmune TCR. Thus this tool is ready for linking to, for example, imaging molecules and will be explored for imaging of human beta-cells.
Work Package 4 -Mucosal Intervention for Tolerance Restoration
Here focus is put on induction of mucosa-mediated tolerance to islet antigens. Orally administered antigen encounters the gut-associated lymphoid tissue (GALT), a well-developed immune network that not only evolved to protect the host from ingested pathogens, but also developed the property of preventing the host from reacting to ingested proteins. Modulation of immune-responses in GALT has been shown to be relevant to prevent/delay autoimmune diabetes onset. 7 In particular we explored the therapeutic potential of an original tool introduced by SME ActoGeniX, in which recombinant L. lactis (ActoBiotics™) is a carrier for peptides, in association with immunomodulatory molecules, allowing delivery of antigen to the GALT. We demonstrated that introduction of beta-cell autoantigens, in particular proinsulin and glutamic acid decarboxylase (GAD), combined with IL-10 delivery and a short course of subtherapeutic doses of antiCD3 antibodies can reverse diabetes in newly diagnosed diabetic NOD mice in over 60 % of cases. This therapeutic effect is combined with the induction of CD4+CD25+FoxP3+ regulatory T cells. By using genetically manipulated models (FoxP3-DTR NOD mice), we could demonstrate that eliminating the FoxP3+ T cells, broke the tolerance installed by the ActoBiotics™ therapy. 8, 9 Clinical grade strains of L. lactis (stably genomically In this distinctive WP, we focus on the role of the beta-cell in its own destruction and specifically on the way in which the immune system and the beta-cell communicate. We have obtained significant insights in the gene networks induced by IL-1b and tumour necrosis factor alpha (TNFa) as well as genes downstream of STAT-1 and IRF-1 using microarray and proteomic techniques in mouse and rat models for T1D
and by RNA sequencing of human islets. A role for several candidate genes for T1D, in beta-cell responses to viral infections has been identified. [10] [11] [12] This was the first evidence that candidate genes for T1D may act at the beta-cell level, modulating both beta-cell apoptosis 16 Now the first data on polymorphisms on genes involved in the VitD metabolism, transport or action are emerging and to our greatest satisfaction patterns of associations are emerging. Of interest, the same polymorphisms are emerging both in DC and in T lymphocytes predicting effects of VitD, thus opening truly the possibility of personalised medicine and selection of those individuals who may benefit most or not at all from a treatment involving VitD.
Expected Final Results and Potential Impact
The predicted impact of the present project is considerable, both on a scientific and a therapeutic level. We have managed to execute this work with great energy, with all partners contributing to the goals of the project.
The cell therapies, the antigen-based approaches, the exploitation of the natural immunomodulators and, of great interest, the introduction of the new tools for tolerance induction, all hold great promise. Research has progressed well in all WPs (see Table 1 ), with 32 out of 37 of the deliverables reached to date, and the first steps to the clinic are within reach. Many interactions have also taken place between our NAIMIT consortium and other FP7 consortia dealing with T1D. In the dissemination arena, the up-to-date internet page has attracted an important audience. Also, the number of scientific publications has increased from 11 in year one to 44 in year 4, with many collaborative publications.
In conclusion, NAIMIT was a project aimed at bringing together a consortium of scientists with the purpose of studying the interplay between the beta-cell and the immune system that lead to T1D, in order to better understand the disease and put forward therapeutic solutions.
Our mission is not finished, we did not cure T1D, but many of our efforts are at the brink of being tested in humans. The partners of NAIMIT all have the feeling 'if only we could continue …', but unfortunately the FP7 programme is ending and alternative funding needs to be found.
The positive point is that one of the first calls within the Innovative Medicines Initiative 2 (IMI2) initiative of the EU has 'T1D' as a target.
However, IMI2 financing is quite different from FP7, as it is much more applied and industry driven, thus preventing the whole NAIMIT consortium to proceed into this initiative. Within Horizon 2020 we are eagerly awaiting for T1D to come onto the horizon. n
